Stock · Nasdaq Helsinki
Should you buy Revenio Group stock?
A Finnish medical-technology company focused on ophthalmic diagnostic devices, best known for its iCare eye-pressure instruments. Here is our rating, the real trade-offs and how to buy the share.
Key points
- Nasdaq Helsinki: REG1V. Finnish medical-technology company, quoted in euros, held in an ordinary brokerage account.
- Focused on ophthalmic diagnostic devices, best known for iCare tonometers (eye-pressure measurement).
- A niche, quality med-tech franchise with an international customer base.
- A smaller-cap growth name: potentially higher volatility and a valuation to watch.
01Our review
Revenio Group at a glance
Revenio Group is a Finnish medical-technology company, headquartered in Vantaa, focused on ophthalmic diagnostics, the devices used to detect and monitor eye disease. It is best known for its iCare tonometers, instruments that measure intraocular (eye) pressure, a key screening test for conditions such as glaucoma. As a specialised med-tech franchise selling to eye-care professionals worldwide, Revenio combines a focused product niche with structural demand from ageing populations and rising screening. The trade-offs are those of a smaller-cap growth company: it is more exposed to single-market or single-product dynamics than a diversified group, and a quality growth name can carry a demanding valuation.
Strengths
- Niche med-tech leader: a focused, well-regarded franchise in ophthalmic diagnostics, best known for iCare tonometers.
- Structural demand: ageing populations and rising eye-disease screening support long-term demand.
- International reach: sells to eye-care professionals across many markets.
Watch-outs
- Smaller-cap risk: more concentrated on specific products and markets than a diversified group, with potentially higher volatility.
- Valuation to watch: a quality growth franchise can trade at a demanding multiple.
- Euro-denominated: currency risk for an investor based outside the eurozone.
02Snapshot
Revenio Group in brief
Fundamentals verified as of July 16, 2026.
04Our verdict
Our verdict, backed by sources
Quality niche med-tech, valuation to watch
A focused, well-regarded ophthalmic-diagnostics franchise with structural demand tailwinds, but a smaller-cap growth name whose valuation and volatility deserve attention.
This is analysis, not advice. The bull case: Revenio Group is a focused, well-regarded medical-technology franchise in ophthalmic diagnostics, best known for its iCare tonometers. Ageing populations and rising eye-disease screening provide a structural demand tailwind, and the company sells to eye-care professionals across many markets.
The bear case: as a smaller-cap company, Revenio is more exposed to single-product and single-market dynamics than a diversified group, and can be more volatile. A quality growth franchise can also carry a demanding valuation, so the entry price matters.
Our take: a high-quality niche med-tech name with genuine structural tailwinds, best sized as a smaller-cap growth position with attention to valuation and volatility. As always, no invented price target.
05Get started
How to buy Revenio Group stock
Two routes, both from regulated brokers. A broker comparison is further down.
Cash / spot
Buy the real share (cash)
You own the share and receive any dividend. Cost is a commission per order, in euros since Revenio trades on Nasdaq Helsinki. Best for investors who want a quality niche med-tech franchise for the long term.
CFD (leveraged)
Trade via CFD (leverage)
A CFD tracks the price with leverage that amplifies gains and losses; costs are the spread plus overnight financing. On a smaller-cap, more volatile stock this is for risk-aware traders only; most retail CFD accounts lose money.
For a long-term investor, buying the real share from a regulated broker is simplest. Compare brokers on commissions and account currency below.
06Playbook
6 tips for buying Revenio Group stock
-
Understand the niche
Revenio is a focused ophthalmic-diagnostics franchise, best known for iCare tonometers.
-
Value the structural demand
Ageing populations and rising eye-disease screening support long-term demand.
-
Respect smaller-cap risk
A smaller-cap name can be more concentrated and more volatile than a large diversified group.
-
Mind the valuation
Quality growth franchises can trade at demanding multiples: the entry price matters.
-
Mind the euro exposure
Revenio trades in euros: outside the eurozone, factor in conversion costs.
-
Diversify
A smaller-cap growth name should be a measured position in a diversified portfolio.
08Where to invest
Where to buy Revenio Group stock
For Revenio Group, prioritise low commissions on European markets and an account suited to the euro. Compare regulated brokers side by side.
Compare brokers for European stocksRevenio Group stock FAQ
- Revenio Group trades on Nasdaq Helsinki under the ticker REG1V. It is quoted in euros.
- Revenio Group is a Finnish medical-technology company focused on ophthalmic diagnostic devices, best known for its iCare tonometers, which measure intraocular (eye) pressure for the screening and monitoring of conditions such as glaucoma.
- We don't publish one. We refuse to invent a figure or a fake consensus. When a credible, sourced analyst consensus exists we may cite it with its date; otherwise we say we don't have one.
Why trust HelloBrokers on this
Independent editorial team. We are not paid by Revenio Group, and we don't publish invented price targets or a fake bank consensus. Ratings follow our methodology; broker referrals (disclosed on each page) fund our work and never change our verdict.
This content is for information only and is not investment advice, a recommendation or a solicitation. Past performance does not predict future returns. Investing carries a risk of capital loss; CFDs amplify that risk. Do your own research and consider professional advice before investing.